<DOC>
	<DOCNO>NCT00404339</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's dendritic cell mixed peptide may help body build effective immune response kill tumor cell . PURPOSE : This randomized phase I trial study side effect vaccine therapy treating patient head neck cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity intranodally inject autologous dendritic cell ( DC ) load wild-type p53 peptide without T-helper peptide epitope patient squamous cell carcinoma head neck . Secondary - Determine local systemic immunomodulatory effect vaccine patient . OUTLINE : This randomize , pilot study . Patients undergo leukapheresis . The result dendritic cell ( DC ) pulse wild-type ( wt ) p53 peptide without T-helper ( Th ) peptide . Individual autologous vaccine prepare patient . Patients HLA-A2-DR4-negative randomize 1 2 treatment arm ( arm I arm II ) . Patients HLA-A2-DR4-positive assigned arm III . - Arm I : Patients receive autologous DC load HLA-A2.1-restricted wt p53 peptide . - Arm II : Patients receive autologous DC load HLA-A2.1-restricted wt p53 peptide Th tetanus toxoid peptide . - Arm III ( HLA-A2-DR4-positive patient ) : Patients receive autologous DC load HLA-A2.1-restricted wt p53 peptide Th wt p53 peptide . In arm , vaccine administer ultrasonography-guided inguinal intranodal injection 30 minute day 0 , 14 , 28 . After completion study therapy , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Resectable disease Any stage allow Successfully treat curative intent Recurrent disease allow provide follow criterion meet : No evidence disease At least 6 week since prior antitumor therapy Positive HLAA2.1 HLADR4 allele status know Tumor tissue must available No active brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 0 1 Life expectancy ≥ 6 month Granulocyte count &gt; 2,500/mm^3 Lymphocyte count &gt; 700/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin &lt; 0.2 mg/dL Creatinine &lt; 0.2 mg/dL Hemoglobin &gt; 8 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 1 week , , ≥ 2 week study completion No systemic infection coagulation disorder No psychiatric disturbance would preclude obtain informed consent safe conduct protocol HIV negative Hepatitis B surface antigen hepatitis C antibody negative No active malignancy PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 6 week since prior adjuvant radiotherapy chemoradiotherapy No time restriction prior curative therapy No concurrent pharmacological dos steroid form ( topical systemic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage I squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage II squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>tongue cancer</keyword>
</DOC>